Biote Corp Financials
BTMD Stock | USD 6.10 0.10 1.61% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Net Profit Margin | 0.0195 | 0.0206 |
|
| |||||
Return On Assets | 0.0233 | 0.0246 |
|
| |||||
Current Ratio | 2.78 | 4.96 |
|
|
Investors should never underestimate Biote Corp's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Biote Corp's cash flow, debt, and profitability to make informed and accurate decisions about investing in biote Corp.
Net Income |
|
Biote | Select Account or Indicator |
Understanding current and past Biote Corp Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Biote Corp's financial statements are interrelated, with each one affecting the others. For example, an increase in Biote Corp's assets may result in an increase in income on the income statement.
biote Corp Earnings Geography
Please note, the presentation of Biote Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biote Corp's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biote Corp's management manipulating its earnings.
Biote Corp Stock Summary
Biote Corp competes with Encompass Health, Pennant, Ensign, InnovAge Holding, and ModivCare. biote Corp. operates in medical practice-building business within the hormone optimization space. The company was founded in 2011 and is headquartered in Irvine, Texas. Biote Corp operates under Medical Care Facilities classification in the United States and is traded on NASDAQ Exchange.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0906831039 |
CUSIP | 090683103 42087R108 |
Location | Texas; U.S.A |
Business Address | 1875 W Walnut |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | biote.com |
Phone | 844 604 1246 |
Currency | USD - US Dollar |
Biote Corp Key Financial Ratios
Profit Margin | 0.04 % | ||||
Operating Margin | 0.24 % | ||||
Price To Sales | 1.69 X | ||||
Revenue | 185.36 M | ||||
Gross Profit | 90.58 M |
Biote Corp Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 32.6M | 54.3M | 111.6M | 155.3M | 178.6M | 187.5M | |
Other Current Liab | 4.0M | 7.6M | 5.1M | 8.5M | 9.8M | 6.7M | |
Net Debt | 25.1M | 10.6M | 41.2M | 25.9M | 23.3M | 22.3M | |
Retained Earnings | (17.1M) | 4.2M | (44.5M) | (29.4M) | (26.5M) | (27.8M) | |
Accounts Payable | 2.4M | 4.3M | 4.1M | 4.2M | 4.8M | 4.0M | |
Cash | 17.2M | 26.8M | 79.2M | 89.0M | 102.4M | 107.5M | |
Net Receivables | 4.7M | 5.2M | 6.9M | 8.2M | 9.4M | 6.4M | |
Inventory | 4.3M | 9.6M | 11.2M | 20.9M | 24.1M | 25.3M | |
Other Current Assets | 1.6M | 5.5M | 3.8M | 4.2M | 4.9M | 3.5M | |
Total Liab | 49.7M | 50.2M | 169.9M | 191.8M | 220.6M | 114.1M | |
Total Current Assets | 27.8M | 47.1M | 101.2M | 122.3M | 140.7M | 147.7M | |
Short Term Debt | 5.2M | 5.2M | 6.6M | 6.6M | 7.5M | 6.3M | |
Intangible Assets | 2.6M | 4.6M | 5.1M | 5.0M | 5.7M | 4.2M |
Biote Corp Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Tax Provision | 189K | 286K | 388K | 5.9M | 6.7M | 7.1M | |
Net Interest Income | (2.4M) | (1.7M) | (5.1M) | (7.4M) | (6.7M) | (6.4M) | |
Interest Expense | 2.4M | 1.7M | 5.1M | 6.4M | 7.3M | 3.9M | |
Total Revenue | 116.6M | 139.4M | 165.0M | 185.4M | 213.2M | 157.6M | |
Gross Profit | 71.6M | 90.6M | 110.4M | 127.5M | 146.6M | 102.6M | |
Operating Income | 31.8M | 34.6M | (60.7M) | 28.7M | 25.8M | 27.1M | |
Ebit | 31.8M | 34.6M | 6.8M | 6.2M | 5.6M | 5.3M | |
Ebitda | 32.9M | 36.0M | 9.2M | 9.2M | 8.3M | 7.9M | |
Cost Of Revenue | 44.9M | 48.8M | 54.6M | 57.9M | 66.6M | 54.9M | |
Income Before Tax | 29.4M | 32.9M | 1.7M | (123K) | (110.7K) | (105.2K) | |
Net Income | 29.2M | 32.6M | 1.3M | 3.3M | 3.0M | 2.8M | |
Income Tax Expense | 189K | 286K | 388K | 2.7M | 3.1M | 3.2M |
Biote Corp Key Cash Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Change To Inventory | (904K) | (5.8M) | (1.7M) | (6.1M) | (5.5M) | (5.2M) | |
Investments | (1.4M) | (3.8M) | (1.8M) | (22.0M) | (19.8M) | (18.8M) | |
Change In Cash | 6.7M | 9.6M | 52.5M | 9.8M | 11.2M | 19.5M | |
Free Cash Flow | 25.0M | 29.9M | (11.0M) | 24.2M | 21.8M | 14.7M | |
Depreciation | 1.1M | 1.4M | 2.2M | 3.0M | 3.4M | 1.9M | |
Other Non Cash Items | 1.7M | 1.2M | (58.3M) | 19.7M | 17.7M | 18.6M | |
Dividends Paid | 13.3M | 11.4M | 12.9M | 8.7M | 7.8M | 7.4M | |
Capital Expenditures | 1.4M | 3.8M | 1.8M | 2.7M | 3.1M | 2.5M | |
Net Income | 29.2M | 32.6M | 1.3M | 3.3M | 3.0M | 2.8M | |
End Period Cash Flow | 17.2M | 26.8M | 79.2M | 89.0M | 102.4M | 107.5M |
Biote Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biote Corp's current stock value. Our valuation model uses many indicators to compare Biote Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biote Corp competition to find correlations between indicators driving Biote Corp's intrinsic value. More Info.biote Corp is number one stock in return on asset category among its peers. It is rated fifth in profit margin category among its peers fabricating about 0.20 of Profit Margin per Return On Asset. The ratio of Return On Asset to Profit Margin for biote Corp is roughly 4.88 . At present, Biote Corp's Net Profit Margin is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Biote Corp by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.biote Corp Systematic Risk
Biote Corp's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biote Corp volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on biote Corp correlated with the market. If Beta is less than 0 Biote Corp generally moves in the opposite direction as compared to the market. If Biote Corp Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one biote Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biote Corp is generally in the same direction as the market. If Beta > 1 Biote Corp moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Biote Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biote Corp's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biote Corp growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Biote Corp January 7, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Biote Corp help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of biote Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of biote Corp based on widely used predictive technical indicators. In general, we focus on analyzing Biote Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biote Corp's daily price indicators and compare them against related drivers.
Downside Deviation | 4.2 | |||
Information Ratio | 0.0574 | |||
Maximum Drawdown | 39.7 | |||
Value At Risk | (4.74) | |||
Potential Upside | 6.02 |
Complementary Tools for Biote Stock analysis
When running Biote Corp's price analysis, check to measure Biote Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biote Corp is operating at the current time. Most of Biote Corp's value examination focuses on studying past and present price action to predict the probability of Biote Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biote Corp's price. Additionally, you may evaluate how the addition of Biote Corp to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
CEOs Directory Screen CEOs from public companies around the world | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |